Caitlin Murray is a partner in the firm’s Technology & Life Sciences group. Ms. Murray advises public and private companies across the life sciences industry, including biotechnology, pharmaceutical, and medical device companies. Her practice includes public and private securities offerings, such as venture capital investments and public offerings, mergers and acquisitions, and other complex transactions, as well as general corporate matters. She joined Goodwin in 2010.

Areas of Practice
Domaines D’Expertise





Ms. Murray works on a wide variety of public and private securities offerings, including venture capital investments and public offerings, mergers and acquisitions, and other complex transactions. Her practice centers on biotechnology, pharmaceutical, and medical device companies and companies in other technology-driven industries. Ms. Murray also represents companies in these sectors in their ongoing corporate matters.

Her recent client representation include:

  • Abide Therapeutics, Inc., in its $430 million collaboration with Merck in the metabolic disease and diabetes fields, and their $50 million agreement with Celgene to discover and develop Abide Therapeutics’ drugs in inflammation and immunology
  • Aerpio Therapeutics in several rounds of venture financing for $60 million to research vascular disease therapies
  • aTyr Pharma its $76 million Series E financing
  • Brean Capital, LLC  in Cytosorbents Corp’s (NASDAQ:CTSO) $10 million offering
  • Checkmate Pharmaceuticals, Inc. in its $20 million Series A financing
  • Convergent Dental in its $9 million Series B financing
  • Deciphera Pharmaceuticals in its $52 million Series C financing
  • Foundation Medicine, Inc. in its $106 million initial public offering
  • NABsys in several rounds of venture financing for $40 million to advance its genomic analysis technology
  • Naurex in its $80 million Series C financing to advance NMDA receptor modulators in depression and other central nervous system (CNS) disorders
  • Omthera Pharmaceuticals in its $64 million initial public offering
  • Paydiant, a mobile wallet tech company, in its sale to PayPal
  • Royalty Pharma in its $124 million acquisition of royalty interest in CIMZIA® and MIRCERA®
  • Semma Therapeutics in its $44 million Series A financing and separate collaboration agreement with Novartis to develop stem cell therapies for Type 1 diabetes
  • Stifel Nicolaus Weisel as an underwriter in Argos Therapeutics $41 million initial public offering
  • SmartCells, Inc., a private biotechnology company developing a glucose responsive insulin, in its capital raising and ongoing operations as well as its ultimate sale to Merck & Co. for an upfront cash payment as well as potential clinical development and regulatory milestones in excess of $500 million and royalties
  • Vericel Corporation as an underwriter in Aastrom Biosciences $35 million public follow on offering


While in law school, Ms. Murray was an editor of the Washington University Journal of Law and Policy.

In The News









J.D., 2009
Washington University School of Law
B.S., Nuclear Science and Engineering, 2006
Massachusetts Institute of Technology



Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique